Abstract 15921: Prevalence of Suboptimal Non-High-Density Lipoprotein Cholesterol Levels in US Adults With Hypertriglyceridemia: The National Health and Nutrition Examination Survey 2003-2010
Introduction: Non-high-density lipoprotein cholesterol (non-HDL-C) is recommended as a secondary target for patients with hypertriglyceridemia in the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines, and multiple longitudinal cohort studies and meta-analyses have demonstrated that non-HDL-C is superior to low-density lipoprotein cholesterol (LDL-C) as a measure of cardiovascular risk. However, non-HDL-C is not routinely calculated or treated in this patient population. We assessed the prevalence of suboptimal non-HDL-C levels in the National Health and Nutrition Examination Survey (NHANES) to determine proportions of the US population with hypertriglyceridemia not at guideline-recommended goal.
Methods: Fasting blood serum data from NHANES 2003-2010 were used to categorize adults ≥20 years of age with hypertriglyceridemia (triglyceride levels ≥200 mg/dL) by non-HDL-C level according to NCEP ATP III guidelines. SAS 9.2 was used for cross-sectional analyses. The Taylor series expansion method was used for variance estimates.
Results: The estimate of population for the US (50 states plus the District of Columbia) was based on 1,229 observations from the NHANES Complex Survey data. As shown in the sample and projected data in the Table, the majority of patients with hypertriglyceridemia also have abnormal levels of non-HDL-C, with an estimated 6.6 million adults with borderline high non-HDL-C of 130-159 mg/dL, 8.3 million with high levels of 160-189 mg/dL, and 8.8 million with very high levels of ≥190 mg/dL.
Conclusions: This analysis shows that most patients in the US with hypertriglyceridemia also have abnormal levels of non-HDL-C, representing a very high level of residual cardiovascular risk for these patients. As non-HDL-C is readily available without further costs, educational efforts should be intensified to increase awareness of the importance of non-HDL-C and its treatment in this patient population.
- © 2013 by American Heart Association, Inc.